Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

NSCLC Management: Second-Line Options

July 16th 2020

Squamous Cell Frontline Therapy: IMpower 131, KEYNOTE-407

July 16th 2020

CheckMate 817 Overview

July 16th 2020

PD-L1 Combination Therapy Clinical Trials

July 16th 2020

Frontline PD-L1 Monotherapy: KEYNOTE-042 and IMpower110

July 16th 2020

CheckMate-9LA: Histology and Frontline Impact

July 16th 2020

Recent Combination Approval: CheckMate-9LA Regimen

July 16th 2020

CheckMate-227 Regimen Safety Profile

July 16th 2020

ASCO 2020 Data Update: CheckMate 227

July 16th 2020

Nondriver Adenocarcinoma: Determining Therapy

July 16th 2020

Three Key ASCO Studies Showcase Targeted Advances

July 15th 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

NCCN Guidelines Recommend Lurbinectedin as Second-Line Treatment in Relapsed SCLC

July 15th 2020

Lurbinectedin was added to the Clinical Practice Guidelines in Oncology by the National Comprehensive Cancer Network on July 7, 2020 for the treatment of patients with small cell lung cancer.

Pepinemab/Avelumab Combo Shows Early Tolerability and Antitumor Activity in Advanced NSCLC

July 15th 2020

The combination of pepinemab and avelumab was found to be well tolerated and demonstrated initial signals of antitumor activity in patients with advanced stage, non–small cell lung cancer.

New Indication Propels Brigatinib Into the Front Line for ALK-Positive NSCLC

July 15th 2020

Thomas E. Stinchcombe, MD, discusses brigatinib’s mechanism as well as the next steps to advance the treatment paradigm for patients with ALK-positive NSCLC.

Dr. Le on the Design of the VISION Trial in METex14-Mutant NSCLC

July 13th 2020

Xiuning Le, MD, PhD, discusses the design of the phase 2 VISION trial in MET exon 14 skipping—mutant non–small cell lung cancer.

Multidisciplinary Management of Patients With Stage III NSCLC

July 13th 2020

Integrating Perioperative Immunotherapy Strategies in NSCLC

July 13th 2020

Molecular testing in Patients With Metastatic NSCLC

July 13th 2020

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

July 13th 2020

Varied Timing of IO Therapy in Patients With Stage III NSCLC

July 13th 2020